Predictive model for vedolizumab efficacy in moderate-to-severe ulcerative colitis based on computed tomography-derived body compositions and nutritional inflammatory markers
{{output}}
Background: Vedolizumab (VDZ) is a key biologic for moderate-to-severe ulcerative colitis (UC), but therapeutic response varies widely among patients. The combined predictive value of computed tomography (CT)-derived body composi... ...
